Sponsored by
Editor's Pick
Diabetes Remission Indexing
A new Annals of Surgery article offers both pre- and post-operative estimates of remission of T2D: See Section B
MBS Digest
ASMBS frames recurrence after MBS as a treatable disease signal
This ASMBS statement reviews treatment options for patients with inadequate response or weight recurrence after metabolic and bariatric surgery. Rather than presenting recurrence as a single failure mode, the authors organize management across revisional operations, endoscopic therapy, and obesity-modifying medications. The statement is guidance rather than a new trial, so its value lies in synthesis and clinical framing. Its practical message is that postoperative weight trajectory problems should prompt a structured reassessment instead of blame or therapeutic nihilism.
For surgeons, the statement supports a more deliberate post-MBS pathway. Anatomy, eating pattern, medication exposure, mental health, comorbidity status, and biology all matter before choosing revision, endoscopy, pharmacotherapy, or observation. Programs that treat recurrence as chronic disease care will be better positioned than programs that only offer episodic follow-up. The document also strengthens the case for long-term bariatric clinics that can intervene before recurrence becomes severe.
Food addiction after MBS marks a high-risk recovery phenotype
This Obesity Surgery cross-sectional study surveyed 631 women at least 18 months after metabolic and bariatric surgery. Food addiction was present in 19.7% and was associated with higher anxiety frequency, lower physical-activity engagement, higher ultra-processed-food consumption, lower total weight loss, higher current BMI, and greater recurrent weight gain. The design is online, observational, and self-reported, so it cannot prove causality. It does, however, identify a clinically recognizable subgroup whose postoperative course needs more than routine weight checks.
For bariatric teams, the finding argues for longitudinal behavioral and nutrition surveillance after the honeymoon period. Screening for food addiction symptoms, anxiety, physical inactivity, ultra-processed-food intake, and recurrent regain can shape follow-up intensity and referral decisions. The right response is not stigma or procedural blame. It is structured multidisciplinary care that treats eating behavior, mood, activity, and weight trajectory as linked signals.
Fellowship training can coexist with safe bariatric outcomes
This American Journal of Surgery cohort examines bariatric cases in a private teaching hospital with supervised fellows. Procedures performed with fellows had no mortality, ICU admission, or conversion to open surgery, and the study compared complications and weight-loss outcomes against staff and benchmark datasets. As a retrospective single-center training-program analysis, it cannot settle every question about generalizability. It does, however, address a persistent concern in bariatric education: whether advanced trainees compromise outcomes when cases are supervised appropriately.
The practical implication is reassuring for programs trying to expand the bariatric workforce. Fellowship participation should be paired with case selection, graded autonomy, attending presence, and reliable outcome tracking. Surgeons who lead training programs need to measure complications, readmissions, reoperations, operative time, and weight-loss results rather than relying on anecdote. Good supervision can make education and patient safety compatible goals.
Opioid timing matters for overnight desaturation after robotic MBS
This Obesity Surgery retrospective study analyzed 312 patients undergoing robotic-assisted Roux-en-Y gastric bypass or sleeve gastrectomy with continuous monitoring for a median of 14.4 hours after PACU discharge. Intraoperative opioid exposure correlated with lower mean postoperative oxygen saturation and was associated with desaturation burden after adjustment, while PACU and later postoperative opioid doses were not. Desaturation clustered early after PACU discharge, and male sex independently increased risk. The study is observational, but the continuous-monitoring design makes the respiratory signal hard to ignore.
For bariatric programs, the takeaway is not simply “avoid opioids.” It is that timing, multimodal analgesia, OSA risk, CPAP planning, and overnight monitoring have to be managed as one perioperative pathway. Opioid-sparing anesthesia may reduce risk, but it should be paired with clear step-down or ward surveillance protocols. The first postoperative night remains a vulnerable window, especially for patients with obesity, sleep-disordered breathing, and limited respiratory reserve.
Diabetes Remission Index aims to sharpen preoperative counseling
This Annals of Surgery study developed and externally validated prognostic calculators for type 2 diabetes remission after Roux-en-Y gastric bypass or sleeve gastrectomy. The investigators built models that can be used before surgery and then updated with weight-loss information after the procedure. As a retrospective model-development study, the calculator still needs thoughtful calibration before broad use in clinic. The clinical goal is clear: move beyond vague promises when discussing diabetes remission.
Bariatric surgeons counsel patients every week about diabetes outcomes, but remission probability varies with disease duration, medication burden, insulin use, weight loss, and baseline metabolic reserve. A validated calculator could help set expectations, compare procedures, and identify patients who need aggressive postoperative diabetes management. It should not replace judgment or shared decision-making. The best use is as a conversation tool that makes uncertainty more explicit.
GLP-1 lean-mass loss debate needs a patient-specific answer
Medscape reports an ADA 2026 debate on whether lean-mass loss during GLP-1 treatment should worry clinicians. One side emphasized that some lean-mass decline is expected during meaningful weight loss, while the other focused on vulnerable groups such as older adults, postmenopausal women, and patients with sarcopenic obesity. This was expert analysis rather than a single new trial. The useful takeaway is that body composition risk is not evenly distributed across all patients using incretin therapy.
Bariatric surgeons should hear this as a reminder to assess function, not just pounds. Patients arriving before or after MBS may already be on GLP-1 therapy, may have rapid weight loss, or may have poor protein intake and limited resistance training. Frailty, falls, sarcopenia, and low reserve matter when planning surgery or medication sequencing. Protein counseling, resistance exercise, and selective body-composition monitoring are practical safeguards.
Preoperative microRNA work points toward biomarker-guided MBS
This SOARD study used preoperative blood microRNA sequencing to explore predictors of one-year weight-loss response after Roux-en-Y gastric bypass or sleeve gastrectomy. The investigators identified three differentially expressed microRNAs that may relate to postoperative weight-loss response. The cohort was small and exploratory, so the finding is not ready for clinical deployment. It belongs in the early biomarker-discovery category rather than the practice-changing category.
For surgeons, the appeal is obvious: better prediction could improve counseling and treatment selection. The caution is just as important. Bariatric response reflects anatomy, behavior, biology, medications, adherence, socioeconomic factors, and follow-up access; no small biomarker panel can carry that complexity alone. If validated, microRNA signals might eventually complement clinical models, but they should not be used to restrict access to surgery.
Hair loss with GLP-1 therapy remains uncommon but worth naming
Reuters summarizes new analyses in BMJ, JAAD, and a preprint suggesting alopecia diagnoses are rare among GLP-1 users but occur more often than in comparator diabetes-drug groups. One analysis also suggested higher new-onset alopecia rates with tirzepatide than semaglutide. Because the evidence includes observational work and a non-peer-reviewed component, the signal needs cautious interpretation. Still, hair loss is a patient-visible adverse effect that can influence adherence.
Bariatric surgeons know that telogen effluvium can follow rapid weight loss after surgery, and the same counseling logic now applies to medication-associated weight loss. Patients need reassurance, nutrition assessment, medication review, and screening for iron, protein, thyroid, and other contributors when clinically indicated. The marketplace may frame hair loss as a drug scare, but clinicians should frame it as a manageable symptom with multiple possible causes. Good anticipatory guidance can prevent unnecessary discontinuation or anxiety.
Revita data renew interest in procedural weight maintenance after GLP-1s
Fractyl reports randomized sham-controlled REMAIN-1 midpoint data for Revita, a duodenal mucosal resurfacing procedure studied after GLP-1 discontinuation. The company says a single procedure helped maintain more GLP-1-induced weight loss at one year than sham. This is investor-release data rather than a peer-reviewed publication, and the tally flags small numbers, exploratory midpoint findings, and pending pivotal-cohort topline results. The concept, though, is important: what happens after GLP-1 therapy stops?
For bariatric surgeons, the study sits at the intersection of endoscopy, pharmacotherapy, and durability. If procedural metabolic therapy can extend weight maintenance after medication withdrawal, it may create new sequencing conversations. For now, teams should treat the claim as preliminary and watch for full peer-reviewed methods, adverse events, durability, and patient-selection details. The clinical need is real, but company-reported midpoint data should not outrun the evidence.
Ottava authorization brings another robotic platform into upper abdominal surgery
Reuters reports that Johnson & Johnson received FDA marketing authorization for the Ottava robotic surgery system. The authorization covers upper-abdominal general surgery procedures, including gastric bypass and sleeve gastrectomy, with a select-customer U.S. launch planned. For bariatric surgeons, the news is less about one device and more about a maturing competitive robotics market. More platforms may eventually change purchasing leverage, training models, and OR workflows.
New robotics options need more than technical enthusiasm. Programs will want data on docking, ergonomics, conversion, operative time, stapling workflow, leak and bleeding outcomes, length of stay, service contracts, and training burden. Surgeons should also watch how credentialing and proctoring evolve as platforms multiply. Competition may help, but only if it produces measurable value for patients and hospitals.
EndoBarrier trial shows metabolic benefit with a safety signal that cannot be ignored
This Annals of Surgery randomized sham-controlled ENDO Trial studied the EndoBarrier duodenal-jejunal bypass liner in 320 patients with poorly controlled type 2 diabetes and obesity. At 12 months, the device improved HbA1c and total weight loss compared with sham. The tally also notes device-related serious adverse events, including intolerance, hemorrhage, and hepatic abscess. That combination makes the paper clinically interesting and clinically uncomfortable.
For surgeons and bariatric endoscopists, the trial raises the familiar device-therapy question: how much risk is acceptable for metabolic benefit? The answer depends on diabetes severity, alternative treatments, patient preference, reversibility, operator experience, and rescue pathways for complications. Endoscopic metabolic therapies may fill a gap between medication and surgery, but they must earn trust through transparent safety reporting. The efficacy signal matters; the adverse-event profile matters just as much.
Medtronic’s real-time AI platform points toward procedure-aware robotics
MassDevice covers Medtronic’s Touch Surgery Aide, an AI-native surgical computing platform for robotic surgery. The platform uses computer vision and accelerated inference to support real-time procedural guidance, telemonitoring, and postoperative insight. The story is driven by company announcement, so it should be read as a technology-market signal rather than clinical validation. Still, it shows where robotic surgery vendors are moving: from hardware platforms toward data-rich intraoperative support.
Bariatric surgeons should pay attention but stay disciplined. Real-time AI guidance will need evidence that it improves safety, efficiency, training, or outcomes in actual procedures, not just polished demonstrations. Programs should ask who owns the data, how models are validated, how alerts affect workflow, and whether the system performs across variable anatomy and surgeon technique. AI in the OR will matter only if it makes teams better without adding noise.
Obesity-cost commentary keeps the access argument in public view
This editor-submitted LinkedIn commentary from Salvatore Docimo Jr. highlights the healthcare-cost burden tied to obesity care. Because the full post was not extractable by web tools, this item is best treated as professional commentary rather than primary evidence. Its placement in the marketplace section is appropriate: cost framing influences employer coverage, payer policy, patient access, and public perception. The issue is not whether obesity is expensive, but whether systems will pay for effective treatment before complications accumulate.
Bariatric surgeons can use this kind of public commentary to support a broader access message. Untreated obesity drives downstream costs through diabetes, cardiovascular disease, liver disease, sleep apnea, joint disease, and lost productivity. Surgical and medical therapies are often judged by their short-term price while the cost of undertreatment is quietly absorbed elsewhere. The practical task is to connect cost discussions to outcomes, coverage design, and timely referral.
Youth GLP-1 growth and falling surgery rates raise sequencing questions
AJMC covers JAMA Pediatrics data showing that GLP-1 therapy has become the dominant treated-obesity pathway for adolescents and young adults while metabolic and bariatric surgery use has fallen sharply. The article frames a real access and sequencing problem rather than a simple drugs-versus-surgery contest. Medication uptake may reflect availability, patient preference, referral patterns, stigma, insurance rules, and clinician comfort. Falling surgery rates are harder to interpret without knowing who never reached a bariatric evaluation.
For adolescent and young adult care, the concern is undertreatment at both ends. Some patients may do well with medications and never need surgery; others may cycle through therapy interruptions, inadequate response, or access barriers while severe disease progresses. Pediatric and young adult programs need shared pathways that include medication, surgery, behavioral care, family support, and transition into adult care. The goal should be timely treatment selection, not protecting one modality’s market share.
Access gaps remain the limiting step in modern obesity care
Medscape covers ICO 2026 and WHO discussion about building comprehensive obesity-care systems. The report emphasizes prevention, GLP-1 access, bariatric interventions, comorbidity management, and social policy while warning that cost and access gaps remain major barriers. This is conference and policy coverage, not a trial report. Its importance for bariatric surgeons is that the best treatment portfolio still fails when patients cannot reach it.
Surgical programs sit inside this access problem every day. Coverage exclusions, prior authorization, drug shortages, geographic gaps, stigma, and fragmented referral networks all shape who receives care. Surgeons should argue for comprehensive obesity treatment while also measuring their own access bottlenecks: referral completion, insurance denial, time to consult, time to operation, and postoperative retention. Advocacy is stronger when paired with local data.
Novo and Lilly rivalry keeps GLP-1 pricing and availability under scrutiny
Reuters summarizes pricing, access, and availability issues for Novo Nordisk and Eli Lilly obesity drugs. The report also notes Novo’s lawsuit over comparative-effectiveness advertising and CMS expansion of a lower-cost GLP-1 pilot. This is a marketplace story, not a clinical efficacy comparison. It shows how quickly obesity pharmacotherapy has become a pricing, advertising, coverage, and supply-chain battleground.
For bariatric surgeons, the commercial fight matters because it changes patient behavior before consultation. Patients may arrive after interrupted therapy, cash-pay treatment, coupon loss, dose rationing, compounded alternatives, or payer-mandated switches. Surgical counseling needs a careful medication history that includes access and affordability, not only dose and response. Programs should be ready to explain how surgery fits when medication is effective but unavailable, unaffordable, or not durable.
Find this useful? Forward it to a colleague.
MBS Digest is free and built for the metabolic surgery and obesity medicine community. A peer recommendation is worth more than any ad.
The AI Agent You Can Trust
The best assistants don't multitask their attention across a hundred tools. Neither does Catch. It's an AI agent that focuses on one thing — the admin work you'd rather not touch — and does it exceptionally well.
Scheduling, flights, restaurants, follow-ups, vendors, clients. You hand it over; Catch handles the back-and-forth and comes back with it done.
No context-switching. No dropped balls. Just your admin, quietly cleared — so your focus stays on the work only you can do.
Meet the agent built for admin, and it'll be ready to work before your next meeting.
Get started at catchagent.ai — and give your attention back to what matters.